Whether it's our working with corporations and assisting student entrepreneurs or spinning out research, I hope that you enjoy reading about all our enterprise activities from across UCL in this review.
Stephen Caddick, Vice-Provost (Enterprise)
Business letters: October 20
18 October 2013
YOU say that turning university science projects into big companies is mostly impossible (“Imperial needs to pick more winners”, last week). Yet the acquisition of Spirogen by Astra Zeneca for $440m (£272m) last week shows that substantial returns to investors are possible from university research.
Read: The Sunday Times